key: cord-0869153-ju34b80e
authors: Jindal, Ankur
title: Outcomes in chronic hepatitis B infection and COVID‐19 – Not always benign !
date: 2021-08-13
journal: Hepatology
DOI: 10.1002/hep.32108
sha: ecd969254e769aeeaa5d6524f412f25ade8632b4
doc_id: 869153
cord_uid: ju34b80e

We read with great interest the article by Cheuk‐Fung Yip et al. concluding that current or past chronic hepatitis B (CHB) infections were not associated with more liver injury and mortality in COVID‐19(1). The study design was retrospective with lot of missing data which makes the interpretation of results difficult. The acute liver injury in the presence of COVID‐19 is multifactorial and in the absence of liver biopsy, it is often difficult to determine the actual cause.

Email: ankur.jindal3@gmail.com, Phone: +91 9582670984

We read with great interest the article by Cheuk-Fung Yip et al. concluding that current or past chronic hepatitis B (CHB) infections were not associated with more liver injury and mortality in COVID-19 1 . The study design was retrospective with lot of missing data which makes the interpretation of results difficult.

The acute liver injury in the presence of COVID-19 is multifactorial and in the absence of liver biopsy, it is often difficult to determine the actual cause.

In the current study, only 3-6% patients with CHB had liver cirrhosis. Patients with hepatitis B related cirrhosis present unique challenges -1) Risk of treatment related severe hepatitis B reactivation and subsequent hepatic decompensation and mortality rates upto 80%. 2) Immune dysfunction that can lead to increased susceptibility to infection and aberrant inflammatory response during infection -collectively known as cirrhosis-associated immune dysfunction (CAID) 2 . Therefore, the pre-existing liver disease severity is important and may predict the incidence and severity of acute liver injury. Data on clinical outcomes for these difficult-to-treat patients in the present study is limited. In the SECURE-Cirrhosis and COVID-Hep registries, hepatic decompensation events and mortality were more frequent with increasing severity of liver disease 3 . Moreover, severe COVID-19 might also precipitate acute-on-chronic liver failure 5 .

Besides liver disease severity, mortality in COVID-19 is also determined by severity of COVID-19 at hospital admission and standards of intensive care unit (ICU) care. Most of the specific drugs for moderate to severe COVID-19 disease including remdesivir, lopinavir-ritonavir, tolicizumab and high dose dexamethasone are contraindicated in the presence of severe liver disease. The current therapeutic armentarium to treat severe COVID-19 for hepatitis B related cirrhosis is limited.

In summary, the clinical relevance of this important study on CHB and COVID-19 disease could have been enhanced by accounting for the above-mentioned factors.

Current and past infections of hepatitis B virus do not increase mortality in patients with COVID-19

Cirrhosis-associated immune dysfunction: distinctive features and clinical relevance

Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: an international registry study